Ken Griffin Immix Biopharma, Inc. Call Options Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding IMMX
# of Institutions
30Shares Held
4.53MCall Options Held
8.9KPut Options Held
1.2K-
Aigh Capital Management LLC Baltimore, MD1.12MShares$2.21 Million0.68% of portfolio
-
Bleichroeder LP New York, NY850KShares$1.67 Million0.43% of portfolio
-
Cable Car Capital LLC San Francisco, CA796KShares$1.57 Million1.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA699KShares$1.38 Million0.0% of portfolio
-
Lynwood Capital Management Inc.405KShares$797,85011.13% of portfolio
About Immix Biopharma, Inc.
- Ticker IMMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,910,100
- Market Cap $27.4M
- Description
- Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specif...